Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibenadet SCHEMBL48983 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL249498 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL678828 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528403 | 0.93 | ABCB11 (0.93) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8527365 | 0.92 | ABCB11 (0.92) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528272 | 0.91 | ADRB2 (0.84) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8533852 | 0.91 | ADRB2 (0.82) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL7829477 | 0.90 | ADRB2 (0.81) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL7842790 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL5386480 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2PDE4AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12233071-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2025-02-25 | — | — | US | disclosed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD (JP) | 2023-08-10 | — | — | US | disclosed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11666582-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233071-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885DRD2 2955/4885 |
| US-11666582-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885DRD2 2955/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | ADRB2 39/4885ADRB1 43/4885DRD2 3194/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | ADRB2 537/4885ADRB1 503/4885DRD2 2753/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | ADRB2 113/4885ADRB1 96/4885DRD2 1617/4885 |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | ADRB2 74/4885ADRB1 72/4885DRD2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.